Calcium-activated chloride channel is involved in the onset of diarrhea triggered by EGFR tyrosine kinase inhibitor treatment in rats

Chloride Channel ◽

Kinase Inhibitor ◽

Egfr Tyrosine Kinase ◽

Inhibitor Treatment

P1.01-96 US Real-World Management of EGFR-Mutated Advanced NSCLC: Survival After First-Line EGFR-Tyrosine Kinase Inhibitor Treatment

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2019.08.811 ◽

2019 ◽

Vol 14 (10) ◽

pp. S398-S399

Author(s):

J. Nieva ◽

K. Reckamp ◽

A. Taylor ◽

B. Thakrar ◽

J. Wong ◽

...

Keyword(s):

Tyrosine Kinase ◽

Real World ◽

Advanced Nsclc ◽

Kinase Inhibitor ◽

First Line ◽

Egfr Tyrosine Kinase ◽

Egfr Mutated ◽

Inhibitor Treatment

Local microwave ablation with continued EGFR tyrosine kinase inhibitor as a treatment strategy in advanced non-small cell lung cancers that developed extra-central nervous system oligoprogressive disease during EGFR tyrosine kinase inhibitor treatment

Medicine ◽

10.1097/md.0000000000003998 ◽

2016 ◽

Vol 95 (25) ◽

pp. e3998 ◽

Cited By ~ 15

Author(s):

Yang Ni ◽

Jingwang Bi ◽

Xin Ye ◽

Weijun Fan ◽

Guohua Yu ◽

...

Keyword(s):

Tyrosine Kinase ◽

Microwave Ablation ◽

Kinase Inhibitor ◽

Small Cell ◽

Small Cell Lung ◽

Lung Cancers ◽

Egfr Tyrosine Kinase ◽

Inhibitor Treatment

Dual-agent molecular targeting of growth factor receptors in hepatocellular cancer: Combining anti-EGFR antibody with an EGFR tyrosine kinase inhibitor

Zeitschrift für Gastroenterologie ◽

10.1055/s-2005-920152 ◽

2005 ◽

Vol 43 (05) ◽

Author(s):

A Hüther ◽

M Höpfner ◽

D Schuppan ◽

H Scherübl

Keyword(s):

Growth Factor ◽

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Hepatocellular Cancer ◽

Growth Factor Receptors ◽

Molecular Targeting ◽

Egfr Tyrosine Kinase ◽

Egfr Antibody

Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

Case Medical Research ◽

10.31525/ct1-nct04007835 ◽

2019 ◽

Author(s):

Keyword(s):

Tyrosine Kinase ◽

Advanced Nsclc ◽

Kinase Inhibitor ◽

Acquired Resistance ◽

Egfr Tyrosine Kinase ◽

Nsclc Patients ◽

Egfr Tki

O-247 Molecular mechanisms of sensitivity and resistance to the HER1/EGFR-tyrosine kinase inhibitor erlotinib (Tarceva™)

Lung Cancer ◽

10.1016/s0169-5002(03)91905-2 ◽

2003 ◽

Vol 41 ◽

pp. S72 ◽

Cited By ~ 6

Author(s):

Roman Perez-Soler ◽

Qun Dai ◽

Yi-He Ling ◽

Marie Lee ◽

Glenn Kroog ◽

...

Keyword(s):

Tyrosine Kinase ◽

Molecular Mechanisms ◽

Kinase Inhibitor ◽

Egfr Tyrosine Kinase

Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial

Molecular Cancer Therapeutics ◽

10.1158/1535-7163.mct-11-0048 ◽

2011 ◽

Vol 10 (6) ◽

pp. 1102-1112 ◽

Cited By ~ 113

Author(s):

Monika E. Hegi ◽

Annie-Claire Diserens ◽

Pierre Bady ◽

Yuta Kamoshima ◽

Mathilde C. M. Kouwenhoven ◽

...

Keyword(s):

Tyrosine Kinase ◽

Phase Ii ◽

Pathway Analysis ◽

Kinase Inhibitor ◽

Phase Ii Trial ◽

Preoperative Treatment ◽

Egfr Tyrosine Kinase

P3.01-073 TPX-0005 with an EGFR Tyrosine Kinase Inhibitor (TKI) Overcomes Innate Resistance in EGFR Mutant NSCLC

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2017.09.1514 ◽

2017 ◽

Vol 12 (11) ◽

pp. S2230

Author(s):

R. Rosell ◽

N. Karachaliou ◽

J.J. Cui ◽

I. Chaib ◽

J. Berenguer ◽

...

Keyword(s):

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Innate Resistance ◽

Egfr Tyrosine Kinase ◽

Egfr Mutant

EGFR Tyrosine Kinase Inhibitor Monotherapy Should Remain the Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2021.08.015 ◽

2021 ◽

Vol 16 (11) ◽

pp. 1793-1797

Author(s):

Sophie Stock-Martineau ◽

Frances A. Shepherd

Keyword(s):

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Line Treatment ◽

First Line ◽

Egfr Tyrosine Kinase ◽

Egfr Mutant ◽

First Line Treatment

EGFR tyrosine kinase inhibitor therapy for lung cancer treatments and their clinical outcomes: A cohort study in Taiwan

Oncology Letters ◽

10.3892/ol.2019.10942 ◽

2019 ◽

Author(s):

Ching‑Hu Chung

Keyword(s):

Lung Cancer ◽

Cohort Study ◽

Tyrosine Kinase ◽

Clinical Outcomes ◽

Kinase Inhibitor ◽

Cancer Treatments ◽

Egfr Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor Therapy

EGFR mutation testing in blood for guiding EGFR tyrosine kinase inhibitor treatment in patients with nonsmall cell lung cancer

Medicine ◽

10.1097/md.0000000000006151 ◽

2017 ◽

Vol 96 (7) ◽

pp. e6151 ◽

Cited By ~ 1

Author(s):

Jin-Qiu Yuan ◽

Yue-Lun Zhang ◽

Hai-Tao Li ◽

Chen Mao

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Cell Lung Cancer ◽

Egfr Mutation ◽

Kinase Inhibitor ◽

Nonsmall Cell Lung Cancer ◽

Inhibitor Treatment ◽

Egfr Mutation Testing